Pulmonary hypertension:

Indications for FLOLAN:

Pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA Class III or IV symptoms, to improve exercise ability.

Adult Dosage:

Give by continuous chronic IV infusion through a central venous catheter. Initially 2ng/kg/min; increase in increments of 1–2ng/kg/min at ≥15min intervals based on response. Decrease dose gradually in 2ng/kg/min decrements at ≥15min intervals until dose-limiting effects resolve.

Children Dosage:

Not established.

FLOLAN Contraindications:

Heart failure due to reduced left ventricular ejection fraction.

FLOLAN Warnings/Precautions:

Avoid abrupt withdrawal or large dose reductions (may cause rebound pulmonary hypertension). Discontinue if pulmonary edema occurs; do not restart. Increased risk for hemorrhagic complications. Monitor BP and symptoms of vasodilation during initiation and after dose changes. Pregnancy. Nursing mothers.

FLOLAN Classification:

Prostacyclin analogue.

FLOLAN Interactions:

Hypotensive effects may be potentiated by diuretics, antihypertensive agents, other vasodilators. Increased risk of bleeding with anticoagulants, antiplatelets.

Adverse Reactions:

Dizziness, jaw pain, headache, musculoskeletal pain, nausea, vomiting, flushing.

How Supplied:

Vials—1 (w. diluent)